Wilkinson GR - Search Results

1

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.

de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. de Morais SM, et al. Among authors: wilkinson gr. J Biol Chem. 1994 Jun 3;269(22):15419-22. J Biol Chem. 1994. PMID: 8195181 Free article.

2

Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.

De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. De Morais SM, et al. Among authors: wilkinson gr. Mol Pharmacol. 1994 Oct;46(4):594-8. Mol Pharmacol. 1994. PMID: 7969038

3

A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin.

Ferguson RJ, De Morais SM, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, Wilkinson GR, Sarich TC, Wright JM, Dayer P, Goldstein JA. Ferguson RJ, et al. Among authors: wilkinson gr. J Pharmacol Exp Ther. 1998 Jan;284(1):356-61. J Pharmacol Exp Ther. 1998. PMID: 9435198

4

An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians.

Ibeanu GC, Blaisdell J, Ghanayem BI, Beyeler C, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Daly AK, Goldstein JA. Ibeanu GC, et al. Among authors: wilkinson gr. Pharmacogenetics. 1998 Apr;8(2):129-35. doi: 10.1097/00008571-199804000-00006. Pharmacogenetics. 1998. PMID: 10022751

5

A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin.

Ibeanu GC, Blaisdell J, Ferguson RJ, Ghanayem BI, Brosen K, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Goldstein JA. Ibeanu GC, et al. Among authors: wilkinson gr. J Pharmacol Exp Ther. 1999 Aug;290(2):635-40. J Pharmacol Exp Ther. 1999. PMID: 10411572

6

Genetic polymorphism of S-mephenytoin 4'-hydroxylation in African-Americans.

Edeki TI, Goldstein JA, de Morais SM, Hajiloo L, Butler M, Chapdelaine P, Wilkinson GR. Edeki TI, et al. Among authors: wilkinson gr. Pharmacogenetics. 1996 Aug;6(4):357-60. doi: 10.1097/00008571-199608000-00009. Pharmacogenetics. 1996. PMID: 8873222 No abstract available.

7

S-mephenytoin 4-hydroxylase is inherited as an autosomal-recessive trait in Japanese families.

Ward SA, Goto F, Nakamura K, Jacqz E, Wilkinson GR, Branch RA. Ward SA, et al. Among authors: wilkinson gr. Clin Pharmacol Ther. 1987 Jul;42(1):96-9. doi: 10.1038/clpt.1987.114. Clin Pharmacol Ther. 1987. PMID: 3595072

8

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.

Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA. Nakamura K, et al. Among authors: wilkinson gr. Clin Pharmacol Ther. 1985 Oct;38(4):402-8. doi: 10.1038/clpt.1985.194. Clin Pharmacol Ther. 1985. PMID: 4042523

9

Induction of propranolol metabolism by rifampicin.

Herman RJ, Nakamura K, Wilkinson GR, Wood AJ. Herman RJ, et al. Among authors: wilkinson gr. Br J Clin Pharmacol. 1983 Nov;16(5):565-9. doi: 10.1111/j.1365-2125.1983.tb02218.x. Br J Clin Pharmacol. 1983. PMID: 6639842 Free PMC article.

10

Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism.

Distlerath LM, Reilly PE, Martin MV, Davis GG, Wilkinson GR, Guengerich FP. Distlerath LM, et al. Among authors: wilkinson gr. J Biol Chem. 1985 Jul 25;260(15):9057-67. J Biol Chem. 1985. PMID: 4019462 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

239 results

Search Page